For a 43-year-old male weighing 293 lb with acute bacterial sinusitis, what antibiotic, dosage, and dosing frequency should be prescribed?

Antibiotic Recommendation for Acute Bacterial Sinusitis

For this 43-year-old male weighing 293 lb (133 kg) with acute bacterial sinusitis, prescribe amoxicillin-clavulanate 875 mg/125 mg twice daily for 5-7 days, or if there are risk factors for resistance (recent antibiotic use in past 4-6 weeks, severe symptoms), use high-dose amoxicillin-clavulanate 2000 mg/125 mg twice daily for 7-10 days. 1, 2

Key Diagnostic Considerations

Before prescribing antibiotics, confirm the patient meets criteria for acute bacterial rhinosinusitis (ABRS) rather than viral rhinosinusitis. The diagnosis requires ONE of the following 2:

• Persistent symptoms ≥10 days without improvement (purulent nasal discharge, nasal congestion, facial pain/pressure)
• Severe symptoms at onset: fever ≥39°C (102°F) with purulent nasal discharge or facial pain for at least 3-4 consecutive days
• "Double-sickening": worsening symptoms after initial improvement from a typical viral URI (new fever, headache, or increased nasal discharge after 5-6 days)

Critical pitfall: Most sinus infections are viral and resolve without antibiotics. Imaging is not needed for diagnosis and should not guide treatment decisions 3, 2.

First-Line Antibiotic Selection

Standard Dosing (No Risk Factors)

Amoxicillin-clavulanate 875 mg/125 mg orally twice daily for 5-7 days 1, 2

This remains the gold standard first-line therapy due to excellent coverage of S. pneumoniae (including penicillin-resistant strains) and H. influenzae, the two most common pathogens 1, 4.

High-Dose Regimen (With Risk Factors)

Amoxicillin-clavulanate 2000 mg/125 mg orally twice daily for 7-10 days 1, 4

Use high-dose therapy if the patient has:

• Recent antibiotic use (past 4-6 weeks)
• Severe symptoms at presentation
• Age >65 years or <2 years
• Recent hospitalization
• Daycare attendance
• Comorbidities or immunocompromised state
• Geographic area with high penicillin-resistant S. pneumoniae prevalence 4, 2

Note on weight: While this patient weighs 293 lb, adult dosing guidelines do not adjust for weight 5. The maximum dose of amoxicillin-clavulanate is 2000 mg twice daily regardless of body weight 1.

Alternative Antibiotics (β-Lactam Allergy)

If the patient has a non-Type I hypersensitivity (e.g., rash):

• Cefpodoxime or cefuroxime or cefdinir 1, 4

If the patient has a Type I hypersensitivity (anaphylaxis):

• Levofloxacin 500 mg once daily for 5-7 days 3, 4, 6
• Moxifloxacin 400 mg once daily for 5-7 days 7, 4

Important caveat: Macrolides (azithromycin, clarithromycin) and trimethoprim-sulfamethoxazole are NOT recommended due to high resistance rates (20-25% bacterial failure) 4. Reserve fluoroquinolones for true penicillin allergy or treatment failure to preserve their effectiveness 7, 3.

Treatment Duration

• Standard therapy: 5-7 days is adequate for uncomplicated ABRS 2
• High-dose or second-line therapy: 7-10 days 2
• Older guidelines suggested 10-14 days, but shorter courses are now evidence-based and reduce adverse effects 1, 2

Reassessment Strategy

Reassess at 3-5 days 1, 2:

• If improving: Complete the antibiotic course
• If no improvement or worsening: Switch to a different antibiotic class
  • If started on standard-dose amoxicillin-clavulanate → switch to high-dose amoxicillin-clavulanate or respiratory fluoroquinolone
  • If started on high-dose amoxicillin-clavulanate → switch to respiratory fluoroquinolone (levofloxacin or moxifloxacin) 1, 4, 2

Red flags requiring urgent specialist referral: Orbital swelling, vision changes, severe headache suggesting intracranial complications, or failure after 21-28 days of appropriate therapy 1.

Adjunctive Therapy

• Intranasal corticosteroids may provide symptomatic benefit 1
• Analgesics (acetaminophen, NSAIDs) for pain relief 3
• Saline irrigation for symptom management 1
• Avoid oral decongestants and antihistamines unless concurrent allergic rhinitis is present 1

Evidence Quality Note

The 2012 IDSA guideline 2 represents the most authoritative and recent comprehensive guidance, though it acknowledges that evidence for antibiotic efficacy in ABRS is moderate quality. The recommendation for amoxicillin-clavulanate as first-line therapy is consistent across all major guidelines 1, 7, 1, 3, 4, 2. Recent data from 2018 8 suggests high-dose immediate-release formulations may provide faster symptom relief but with increased diarrhea risk (15.8% vs 4.8%).